ProQR has reported the first clinical target-engagement data for its Axiomer RNA editing platform, while pricing a share offering and concurrent private placement that includes existing partner Eli Lilly.
Italian pharma Recordati has entered into a license agreement with Ionis Pharmaceuticals, Inc. for exclusive development and marketing rights to zilganersen, an investigational RNA-targeted medicine for the treatment of Alexander disease (AxD), in all countries outside the U.S.
ADC Therapeutics will cut about 17% of its global workforce as it tries to preserve cash and keep Zynlonta’s regulatory strategy on track after a difficult Phase III readout.
Novartis has signed a multi-target oncology discovery deal with Antares Therapeutics, paying $105m upfront for access to the Boston biotech’s small-molecule discovery engine. The agreement could bring Antares up to $1.8bn more in option, development, regulatory and commercial milestones, plus tiered royalties on global net sales that could reach the low double-digit range.
Dutch biotech Leyden Labs has raised €40m from a group of investors to advance its nasal spray approach for protection against influenza and other respiratory viruses.
London’s RQ Bio, a private biotech developing long-acting antibody therapeutics to prevent flu, has raised $115 million (£85.5 million/€101 million) in its Series A financing.
Thalia Therapeutics is acquiring Sanmirna Therapeutics for an initial £3.675 million and up to £13 million in milestone payments, adding the clinical-stage acute myeloid leukemia (AML) candidate miRisten and transforming the company from a preclinical platform into a clinical-stage RNA therapeutics company.
Merck KGaA has partnered with Versant Ventures to launch Saturnus Bio, a new biotech developing precision medicines for rare genetic cardiomyopathies.
UK-based TRIMTECH Therapeutics has raised an additional $14 million, bringing its total seed financing to $47 million.
Sanofi’s Cenrifki (tolebrutinib) has been approved in the EU as the first disability-targeting medicine for adults with secondary progressive multiple sclerosis (SPMS) without relapses in the previous two years.